Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
RSS

FDA clears IND to investigate OrbeShield in GI-ARS

Jan. 7, 2013

Savant obtains NIDA funding for preclinical development of 18-MC

Jan. 7, 2013

Probuphine obtains FDA priority review designation for opioid dependence

Jan. 3, 2013

ALKS-5461 as a novel combination therapy for the treatment of cocaine abuse

Dec. 19, 2012

EMA committee recommends approval of Selincro for alcohol dependence

Dec. 17, 2012

Omeros patents new anti-MASP-2 monoclonal antibodies

Dec. 7, 2012

Varenicline as a potential treatment for methamphetamine dependence

Dec. 7, 2012

Phase IIa trial begins of MediciNova's ibudilast

Nov. 22, 2012

FDA assigns action date for Orexo's Zubsolv NDA

Nov. 19, 2012

Catalyst Pharmaceutical reports results from phase IIb CPP-109 trial

Nov. 9, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 16, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...